Imaging Technology

SEPTEMBER 27, 2023

milla1cf Wed, 09/27/2023 - 15:07 September 27, 2023 — The American Society for Radiation Oncology ( ASTRO ) announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.

Radiation 94

Radiation Radiation Oncology Clinic Disease 94

Imaging Technology

SEPTEMBER 27, 2023

“PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics.

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

Imaging Technology

SEPTEMBER 29, 2023

The findings, which are the latest from a series of studies investigating the benefits of stereotactic body radiation therapy (SBRT) for people diagnosed with prostate cancer, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. weeks (78 Gy) or 20 fractions over four weeks (62 Gy).

Radiation 84

Radiation Radiation Oncology Disease Diagnose 84

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

MARCH 26, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52